Regina Graul, Ph.D., Promoted to Chief Executive Officer
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has...
Pharmaceutical
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical...
EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments
– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in...
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds...
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following...
Applied Therapeutics Reports Second Quarter 2024 Financial Results
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action...
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food...
New Results from AlzeCure’s Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024
STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Cryoport Reports Second Quarter 2024 Financial Results
Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total...
Jennifer Stacey Joins PicnicHealth as Chief Delivery Officer
SAN FRANCISCO, Aug. 6, 2024 /PRNewswire/ -- Today, PicnicHealth, a company dedicated to simplifying observational research, announced the appointment of Jennifer...
Anju Announces New Product to Revolutionize Field Rep Efficiency with Precision-Driven Medical Information
FORT LAUDERDALE, Fla., Aug. 6, 2024 /PRNewswire/ -- Anju Software is proud to introduce MA Knowledge, a mobile application enhancing...
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
Samsung Biologics to embed PSCI principles into business practices for responsible value chain managementSupplier Partnership reaffirms company's commitment to decarbonize...
Spineology® Announces $25 Million Equity Financing
– Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant...
Gelteq Strengthens Partnership with Monash Innovation Labs
Company benefits from robust ecosystem within the university, including premium facilities, talent, and expertiseMELBOURNE, Australia, Aug. 06, 2024 (GLOBE NEWSWIRE)...
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc’s Palmitoylethanolamide...
Clearmind Medicine: New Scientific Publication Shows MEAI’s Potential as a Novel Weight Loss Drug
Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter...
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio’s Patented INTASYL Compound
Phio's INTASYL compound targets aging skin disordersMarlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...